|
|
| | 1H-Inden-1-one, 2,3-dihydro-6-methoxy-5-(4-morpholinyl)-2-[[3-(trifluoromethyl)-2-pyridinyl]methyl]- Basic information |
| | 1H-Inden-1-one, 2,3-dihydro-6-methoxy-5-(4-morpholinyl)-2-[[3-(trifluoromethyl)-2-pyridinyl]methyl]- Chemical Properties |
| Boiling point | 561.5±50.0 °C(Predicted) | | density | 1.322±0.06 g/cm3(Predicted) | | pka | 2.84±0.20(Predicted) |
| | 1H-Inden-1-one, 2,3-dihydro-6-methoxy-5-(4-morpholinyl)-2-[[3-(trifluoromethyl)-2-pyridinyl]methyl]- Usage And Synthesis |
| Description | ARN-6039 (being developed by Arrien), is a Potent, Orally Available Inverse Agonist of RORgammat for Autoimmune Neuroinflammatory Demyelinating Disease. The activity of ARN-6039 against RORt was demonstrated in a RORt-activated IL-17A Prom/LUCPorter assay in HEK 293 cells (360 nM) and in IL-17 release from CD4+T cell assays (220 nM). The compound also possesses ideal CNS drug-like criteria, exhibited excellent pharmacokinetics (%F: 37), pharmacodynamics, and correlative PK/PD and ADME characteristics. | | Uses | ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease. | | References | [1] Vankayalapati, Hariprasad; Yerramreddy, Venkatakrishnareddy. Preparation of dihydroindenone derivatives for use as retinoic acid-related orphan nuclear receptor modulators. US20150072980A1 |
| | 1H-Inden-1-one, 2,3-dihydro-6-methoxy-5-(4-morpholinyl)-2-[[3-(trifluoromethyl)-2-pyridinyl]methyl]- Preparation Products And Raw materials |
|